Davon "nur" 120 Mio im Float, also nicht schon wieder übertreiben ... Deine Fehler mit angeblichen Fakten zu Calypte häufen sich in der letzten Zeit ;-)
Shares Outstanding: 169.32M
Float: 120.60M
% Held by Insiders: 28.78%
% Held by Institutions: 7.53%
fehler.....naja...lach...
deine tollen angepriesenen rapidtests stehen noch gar nicht zum verkauf und solange diesen nicht freigegeben sind bzw. keine umsätze gemacht werden, kannst du nur davon träumen. es entspricht also nicht der realität. deine "spezielle realität" basiert auf reinem wunschdenken.
desweiteren wir die aktienmenge bald auf über 220.000.000 outstanding erhöht werden, auch das ist fakt.
also gut kade, nochmal für dich aus den letzten filings vom 29.10. bzw. 12.11:
hier aus dem filing vom 29.10.
MARKET - 25% MARKET
--------------------------------------------------
Share Price $0.2475 $0.330
--------------------------------------------------
Shares outstanding at
October 22, 2004 169.3 169.3
Shares issuable for $16.5
million financing (1) 66.7 50.0
Anti-dilution shares due 10.3 4.7
and issuable (2)
-----------------------------
Shares outstanding after 246.3 224.0
financing
=============================
% dilution compared to
October 22, 2004 shares 45.5% 32.3%
outstanding
--------------------------------------------------
...We have received regulatory approval to sell our ELISA tests in China, Malaysia, Indonesia, and in parts of Africa. Unfortunately, these laboratory-based tests have not
received significant acceptance in those markets. We believe that there is a
small established market for our current ELISA tests in the United States and a
potential market in certain foreign countries with established medical
diagnostic and treatment infrastructures, as well. We believe, however, that
rapid tests are more suitable in many of the countries in which HIV/AIDS is
epidemic, and particularly so in sub-Saharan Africa and the "next wave"
countries of Russia, China, India and in northern Africa. (S. 16 unten)
...We Have Incurred Losses in the Past and We Expect to Incur Losses in the Future.
We have incurred losses in each year since our inception. Our net loss for the
nine months ended September 30, 2004 was $11.1 million and for the year ended
December 31, 2003 was $26.5 million; our accumulated deficit at September 30,
2004 was $139.0 million. We expect operating losses to continue during 2004 and
into 2005, as we complete the development and/or commercialization of our rapid
tests, complete our domestic manufacturing consolidation and international
technolgy transfers, and conduct additional research and development and
clinical trials for potential new products. (S. 43 mittig)
...If we find it necessary to issue additional common stock to fund our operations in the year following the May 2004 and July 2004 PIPEs, all of our stockholders will
experience dilution; if the terms of the potential future financing require that
we issue shares of our common stock at a price of less than $0.40 per share,
holders of our common stock prior to the 2004 PIPEs will experience even greater
proportional dilution. (S. 44 unten)
...Further, we have incurred a loss from operations in both calendar 2003 and in the first nine months of 2004. We have now completed the technology transfer for our HIV-1 incidence test and have that product available for sale, but we have no experience marketing that test or our rapid tests currently being developed and/or commercialized. If we cannot profitably introduce significant new products on a timely basis and if
these products and our current ELISA tests fail to achieve market acceptance or
generate significant revenues, we may have to seek additional financing, which
may not be available on the timetable required or on acceptable terms, or we may
have to curtail our operations, or both. (S. 48 mittig)
wenn sich hier einer mal richtig informieren sollte und die mal die rosaroten scheuklappen abziehen sollte, dann bist du es!!!